

**BUSINESS INSURANCE<sup>®</sup>**

# **CANNABIS & HEMP CONFERENCE**


**OCTOBER 24-25, 2019 | MARRIOTT MARQUIS | NEW YORK CITY**

**Medical Professional Liability  
Implications of Medicinal  
Cannabis**

Lori Semlies, Esq. Wilson, Elser, Moskowitz, Edelman & Dicker  
Monica Bopha Taing, PharmD, RPh  
Douglas R. Shaw, Associate General Counsel, Nuvance Systems  
Zachary Palace, M.D. Medical Director of Hebrew Home for the Aged at Riverdale

# CBD (Cannabidiol) vs. THC (Tetrahydrocannabinol)

- Scientifically, hemp & marijuana are similar plants
- Different genetic profiles (genus & species)
- THC & CBD: phytocannabinoids (natural compounds)
- Marijuana: commonly greater THC concentration
  - THC can induce a mind-altering “high” (euphoria) or hunger
- Hemp: naturally greater CBD concentration
  - CBD does not cause euphoria: can reduce anxiety, inflammation, pain, etc.
- Hemp is used for food, fuel, fabric, fiber, etc.



BUSINESS INSURANCE.

CANNABIS & HEMP CONFERENCE


OCT 24-25 | MARRIOTT MARQUIS | NEW YORK

#BI\_CANNABIS

# The Endocannabinoid System

Mammals evolved to have a unique ECS

- Function of the ECS:
  - **Homeostasis**
- Components of the ECS:
  - Receptors
  - Ligands
  - Enzymes



The ECS acts as a biological balancing mechanism to regulate normal function in the body including memory, mood, eating, sleeping, forgetting, and protecting cellular function.

The two most common methods for consuming cannabis are: inhalation (smoking or vaporizing) and ingestion (prescription synthetic capsules or edibles).

**Immune system consists of:**

- Tonsils
- Spleen
- Plus other cells and body systems

Source: Americans For Safe Access (2018). Medical Marijuana Access In the United States. A Patient-Focused Analysis of the Patchwork of State Laws. Washington, DC: Americans for Safe Access.

BUSINESS INSURANCE.


CANNABIS & HEMP CONFERENCE

OCT 24-25 | MARRIOTT MARQUIS | NEW YORK


#BI\_CANNABIS

# Cannabis Pharmacology

- Mechanism of action in the ECS



- Cannabis contains phytochemicals
  - **Cannabinoids**
  - **Terpenes**
  - **Flavonoids**



BUSINESS INSURANCE.

CANNABIS & HEMP CONFERENCE

OCT 24-25 | MARRIOTT MARQUIS | NEW YORK

#BI\_CANNABIS

# Potency & Product Formulations

## DELIVERY METHODS

PATIENTS USE MANY METHODS TO TAKE CANNABIS. THE METHOD USED CAN DEPEND ON PERSONAL CHOICE, THE MEDICAL CONDITION BEING TREATED, THE AGE OF THE PATIENT, THE PATIENT'S TOLERANCE FOR THE METHODS, ETC.

## TOPICAL

**Product types:** lotions, salves, oils  
**Expected onset:** a few minutes  
**Duration:** 1-4 hours



## INHALATION

**Types of products:** whole plant, oils, waxes, and concentrates  
**Expected onset:** 0-10 minutes  
**Duration:** 1-4 hours




## BUCCAL

**Product types:** alcohol-based tinctures, lozenges  
**Expected onset:** 0-60 minutes  
**Duration:** 1-8 hours



## INGESTION

**Product types:** edible products, beverages, teas, capsules  
**Expected onset:** 30 to 90 minutes  
**Duration:** Up to 8 hours



**Remember...  
start low, go slow!**

Source: Americans For Safe Access (2018). Medical Marijuana Access In the United States. A Patient-Focused Analysis of the Patchwork of State Laws. Washington, DC: Americans for Safe Access.


BUSINESS INSURANCE.

CANNABIS & HEMP CONFERENCE

OCT 24-25 | MARRIOTT MARQUIS | NEW YORK


#BI\_CANNABIS

# Dose-Dependent Short-Term & Long-Term Effects



Source: Hill MN, et al. Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder. *Neuropsychopharmacology*. 2018 Jan;43(1):80-102. doi: 10.1038/npp.2017.162. Epub 2017 Jul 26. Review. PubMed PMID: 28745306; PubMed Central PMCID: PMC5719095.

When a patient is considering medical marijuana as a potential alternative, consulting with a healthcare professional regarding potential side effects is vital



Source: National Academies of Sciences, Engineering, and Medicine. (2017). *The Health Effects of Cannabis and Cannabinoids: The current state of evidence and recommendations for research*. Washington, DC: The National Academies Press

BUSINESS INSURANCE.

CANNABIS & HEMP CONFERENCE

OCT 24-25 | MARRIOTT MARQUIS | NEW YORK

#BI\_CANNABIS

# STANDARD OF CARE?

- Provider –Patient relationship
- History and Physical
- Formulating a diagnosis
- Treatment plan—with informed consent discussion
- Monitoring efficacy of treatment
  
- AND OF COURSE.....DOCUMENTATION!

BUSINESS INSURANCE.

**CANNABIS & HEMP CONFERENCE**

OCT 24-25 | MARRIOTT MARQUIS | NEW YORK

#BI\_CANNABIS

# Medical Use of Cannabis

- As cannabis in its various forms becomes legal in many of our States it is important for the medical community to react to the availability of these drugs
- It is important for physicians in States where marijuana is only legal for medical uses, that there continue to be restrictions on how and when cannabis can be certified and/or obtained – and each State’s rules are different
- Considerations for physicians – will they practice in multiple States where the laws may be different as to the legality of cannabis?
- More considerations for physicians – are they treating patients who have medical cards in more than one State OR in a State where it is legal but living in a State where it is not?
- How readily available is cannabis to the patients in your State?
- Challenge is that our patients are accessing the drugs before the medical community truly understands it

**BUSINESS INSURANCE.**

**CANNABIS & HEMP CONFERENCE**

**OCT 24-25 | MARRIOTT MARQUIS | NEW YORK**

**#BI\_CANNABIS**

# Considerations: Medical Use of CBD

- Part of the concern with CBD use by patients is that it is being sold as a supplement and not a medication. As such, patients may not feel that they need to disclose their use of CBD to their physician.
- Research suggests any side effects that do occur with CBD use are likely the result of drug-to-drug interactions between CBD and other medications you may be taking.
  - So – for physicians, it will be critical to understand how CBD could interact with other medications.
- New research is also beginning to look at the effect of CBD on the liver in those patients taking it for longer periods.

BUSINESS INSURANCE.

**CANNABIS & HEMP CONFERENCE**

OCT 24-25 | MARRIOTT MARQUIS | NEW YORK

#BI\_CANNABIS

# Use of CBD – Malpractice Risk

- While the vast majority of the science indicates CBD oil is safe for use and consumption, it does pose a few risks that, if not properly understood, could lead to malpractice claims.
- CBD Oil is an inhibitor. What this means is that it can act to keep other medications from being processed by the body as quickly as intended so the drug remains in the patient's system longer than anticipated causing unwanted side effects or potential for overdose. Here are some examples:

Steroids	Anesthetics
HMG CoA reductase inhibitors	Antipsychotics
Calcium channel blockers	Antidepressants
Antihistamines	Anti-epileptics
Prokinetics	Beta blockers
HIV antivirals	PPIs
Immune modulators	NSAIDs
Benzodiazepines	Angiotension II blockers
Antiarrhythmics	Oral hypoglycemic agents
Antibiotics	Sulfonylureas

BUSINESS INSURANCE.

**CANNABIS & HEMP CONFERENCE**

OCT 24-25 | MARRIOTT MARQUIS | NEW YORK

#BI\_CANNABIS

# Considerations: Medical Use of Marijuana (THC)

- Heart disease: Marijuana might cause rapid heartbeat, short-term high blood pressure. It might also increase the risk of a having heart attack.
- A weakened immune system: Cannabinoids in marijuana can weaken the immune system, which might make it more difficult for the body to fight infections.
- Lung diseases: Long-term use of marijuana can make lung problems worse. Regular, long-term marijuana use has been associated with lung cancer and also with several cases of an unusual type of emphysema, a lung disease.
- Seizure disorders: Marijuana might make seizure disorders worse in some people; in other people it might help to control seizures.

BUSINESS INSURANCE.

**CANNABIS & HEMP CONFERENCE**

OCT 24-25 | MARRIOTT MARQUIS | NEW YORK

**#BI\_CANNABIS**

# Malpractice Risks - THC

- Physicians are suddenly faced with having to know how cannabis can interact with other medications – EVEN IF THEY DO NOT CERTIFY FOR ITS MEDICAL USE
  - Example – Oncologist is working with a cancer patient who discloses use of cannabis for control of pain. Oncologist did not certify the patient for its use, but now needs to know how it could affect all of the other medications the patient takes for their cancer.
  - What if he/she prescribes a medication that is contraindicated with cannabis?
  - How will they educate themselves on those medications?
  - What is the effect of long term use of Marijuana?

BUSINESS INSURANCE.

**CANNABIS & HEMP CONFERENCE**

OCT 24-25 | MARRIOTT MARQUIS | NEW YORK

#BI\_CANNABIS

# Diverse Delivery Methods

- NY & NJ Medical Marijuana Program (MMP) approve different formulations:
- NY – non-smokable formulations
  - Oils/Pens
  - Tincture/drops
  - Gels, creams, lotions, or ointments
  - Capsules
  - Vaping (vaporizing)
- NJ – permits smokable formulations
  - Cannabis flower (bud) for vaping (preferred) or smoking (typically not recommended)
  - Oils/Pens
  - Tincture/drops
  - Gels, creams, lotions, or ointments
  - Capsules

BUSINESS INSURANCE.

**CANNABIS & HEMP CONFERENCE**

OCT 24-25 | MARRIOTT MARQUIS | NEW YORK

#BI\_CANNABIS

# NOT ALL PRODUCTS ARE THE SAME

- Oral ingestion peaks in 1-6 hours and then has a 20-30 minute half life
- Inhalation peaks at 2 to 10 minutes and decline begins within 30 minutes
- Potency levels vary
- Ration of THC to CBD varies

BUSINESS INSURANCE.

**CANNABIS & HEMP CONFERENCE**

OCT 24-25 | MARRIOTT MARQUIS | NEW YORK

#BI\_CANNABIS

# Use of Marijuana Where Legal for Recreational – Malpractice Risk

- Physicians are suddenly faced with patients asking them what they think about using cannabis
  - Example – General primary care physician is treating a patient with a diagnosis of severe rheumatoid arthritis. The patient is in constant pain and asks the doctor what she thinks about her using cannabis recreationally to ease the pain. The doctor says that it might be a good option for the patient to deal with her pain.
  - Patient obtains and uses cannabis as it is legal for recreational use
  - Patient has an adverse reaction to the cannabis and blames the physician saying that he/she said it was a good idea to use it.

BUSINESS INSURANCE.

**CANNABIS & HEMP CONFERENCE**

OCT 24-25 | MARRIOTT MARQUIS | NEW YORK

**#BI\_CANNABIS**

# LACK OF INFORMED CONSENT

## RISKS:

Drug interaction

Increased risk of falls

Short term memory impairment

Increased confusion

Pregnancy/breast feeding, fertility

Impaired brain development

Increased risk of suicidal thoughts

Increase of symptoms of bipolar disorder

Smoking increases risk of respiratory illnesses

Increased risk of lung cancer in tobacco user who inhale

Dependence/addiction


**BUSINESS INSURANCE.**

**CANNABIS & HEMP CONFERENCE**

**OCT 24-25 | MARRIOTT MARQUIS | NEW YORK**

**#BI\_CANNABIS**

# Considerations for use in Hospital Setting



BUSINESS INSURANCE.

**CANNABIS & HEMP CONFERENCE**

OCT 24-25 | MARRIOTT MARQUIS | NEW YORK

#BI\_CANNABIS

# Balancing Act

BUSINESS INSURANCE.

**CANNABIS & HEMP CONFERENCE**

OCT 24-25 | MARRIOTT MARQUIS | NEW YORK

**#BI\_CANNABIS**

# Marijuana & Federal Law

## *Remains illegal*

1. Schedule I controlled substance (21 U.S.C. §812[c][10]);
2. This means, pursuant to 21 U.S.C. §812(b)(1)(emph. supp.):
  - A. The drug or other substance has a **high potential for abuse**.
  - B. The drug or other substance has **no currently accepted medical use** in treatment in the United States.
  - C. There is a **lack of accepted safety for use** of the drug or other substance under medical supervision.

Problem: In theory, any program designed to enable inpatients to use medical marijuana (and any program that gives a facility “possession” of medical marijuana) jeopardizes Medicare participation and could invite sanctions...

BUSINESS INSURANCE.

**CANNABIS & HEMP CONFERENCE**

OCT 24-25 | MARRIOTT MARQUIS | NEW YORK

**#BI\_CANNABIS**

# Marijuana & Joint Commission

## Joint Commission

The Joint Commission Standard MM.03.01.05 policy that states: “The hospital safely controls medications brought into the hospital by patients, their families, or licensed independent practitioners.”<sup>1</sup>

*This standard includes the following elements of performance:*

- The hospital defines when medications brought into the hospital by patients, their families, or licensed independent practitioners can be administered.
- Before use or administration of a medication brought into the hospital by a patient, his or her family, or a licensed independent practitioner, the hospital identifies the medication and visually evaluates the medication's integrity.
- The hospital informs the prescriber and patient if the medication brought into the hospital by patients, their families, or licensed independent practitioners is not permitted.

1. The Joint Commission. Revisions to the medication management standards regarding sample medications. December 18, 2013. [http://www.jointcommission.org/assets/1/6/Sample-Medications\\_HAP.pdf](http://www.jointcommission.org/assets/1/6/Sample-Medications_HAP.pdf).

BUSINESS INSURANCE.

**CANNABIS & HEMP CONFERENCE**

OCT 24-25 | MARRIOTT MARQUIS | NEW YORK

**#BI\_CANNABIS**

# Patient Need & Safety

- Any patient who reports the use of medical marijuana at home and requests to use their medical marijuana while in the hospital will be asked for their New York State Department of Health Medical Marijuana Program ID card. A copy of the card will be scanned into the medical record.
- The patient or registered caregiver is responsible for the medication at all times.
- Only medical marijuana obtained from a NYS dispensary will be permitted in its original packaging.
- If at any time, the patient's clinical status suggests that the potential risk of using medical marijuana outweighs the potential therapeutic benefits of its use, the attending physician may state that the patient is not allowed to use medical marijuana during the hospital stay.

**BUSINESS INSURANCE.**

**CANNABIS & HEMP CONFERENCE**

**OCT 24-25 | MARRIOTT MARQUIS | NEW YORK**

**#BI\_CANNABIS**

Patient comes through the door with medical marijuana – now what?

**BUSINESS INSURANCE.**

**CANNABIS & HEMP CONFERENCE**


OCT 24-25 | MARRIOTT MARQUIS | NEW YORK

**#BI\_CANNABIS**

# *Turn a blind eye?*



*Patient Care & Safety*



*Claims and Lawsuits*



This Photo by Unknown Author is licensed under CC BY-NC

*Sanctions & Fines*

**BUSINESS INSURANCE.**

**CANNABIS & HEMP CONFERENCE**

OCT 24-25 | MARRIOTT MARQUIS | NEW YORK

**#BI\_CANNABIS**

*Can we get a policy?*

*Who's at  
the table?*

BUSINESS INSURANCE.

**CANNABIS & HEMP CONFERENCE**

OCT 24-25 | MARRIOTT MARQUIS | NEW YORK

**#BI\_CANNABIS**

# So Many Questions

How do we  
document?

This Photo by Unknown Author is licensed under CC BY-SA

**BUSINESS INSURANCE.**

**CANNABIS & HEMP CONFERENCE**

OCT 24-25 | MARRIOTT MARQUIS | NEW YORK

**#BI\_CANNABIS**

# *Some Ways to Lock it up...*

- “The hospital is not responsible for storing or handling marijuana products. The medication will be secured in the patient’s room.”
- *Seems like a simple idea...Putting it into practice is not as easy as it seems.*



BUSINESS INSURANCE.

**CANNABIS & HEMP CONFERENCE**

OCT 24-25 | MARRIOTT MARQUIS | NEW YORK

**#BI\_CANNABIS**

**BUSINESS INSURANCE<sup>®</sup>**

# **CANNABIS & HEMP CONFERENCE**

**OCTOBER 24-25, 2019 | MARRIOTT MARQUIS | NEW YORK CITY**

**Medical Cannabis in the  
Nursing Home**

Zachary J. Palace MD CMD FACP  
Medical Director, Hebrew Home at Riverdale



# History of Cannabis

- 2700 BC – China
- 1400 BC – India
- 1000 BC - Tibet
- 70 AD – Greece
  
- 1842 – United Kingdom
- 1850 – United States

BUSINESS INSURANCE.

**CANNABIS & HEMP CONFERENCE**

OCT 24-25 | MARRIOTT MARQUIS | NEW YORK

#BI\_CANNABIS

# Approved indications - NYS

- Multiple Sclerosis
- Parkinson's Disease
- Huntington's Disease
- ALS
- Seizures
- Spinal cord injury
- Chronic or acute pain
- Neuropathy
- Cancer
- Inflammatory bowel dis
- AIDS
- HIV
- PTSD
- Opioid use disorder

BUSINESS INSURANCE.

**CANNABIS & HEMP CONFERENCE**

OCT 24-25 | MARRIOTT MARQUIS | NEW YORK

**#BI\_CANNABIS**

# Challenges In the Nursing Home

- Federal law – skilled nursing facility.  
Restrictions on possession, administration
- State law – patient.  
Rights of the individual NYS resident

How can we find a safe (and legal) balance?

BUSINESS INSURANCE.

**CANNABIS & HEMP CONFERENCE**

OCT 24-25 | MARRIOTT MARQUIS | NEW YORK

#BI\_CANNABIS

# Medical Marijuana NYT, February 2017



BUSINESS INSURANCE.

CANNABIS & HEMP CONFERENCE

OCT 24-25 | MARRIOTT MARQUIS | NEW YORK

#BI\_CANNABIS



# JAMDA

**amda**  
The Society for Post-Acute and Long-Term Care Medicine

# January 2019

Pragmatic Innovations in Post-Acute and Long-Term Care Medicine

Feasible new, practical products or approaches intended to improve outcomes or processes in post-acute or long-term care

## Medical Cannabis in the Skilled Nursing Facility: A Novel Approach to Improving Symptom Management and Quality of Life

 Check for updates

Zachary J. Palace MD, CMD\*, Daniel A. Reingold MSW, JD

Hebrew Home at Riverdale, Bronx, NY

### ABSTRACT

Throughout the millennia, the cannabis plant has been utilized as a recognized therapy for pain relief and symptom management. Following the Prohibition-era stigmatization and criminalization of all forms of cannabis of the early 20th century, there has been a recent nationwide and worldwide resurgence in interest and use of the cannabinoid compounds extracted from the cannabis plant, that is, medical cannabis. Although at the Federal level, cannabis remains a Schedule I substance, 31 states have already decriminalized possession and use of medical cannabis for specific diagnoses. It is noteworthy that many of these indicated diagnoses are prevalent in the skilled nursing facility (SNF). This creates regulatory concerns as SNFs and other healthcare facilities must maintain compliance with Federal laws, while balancing the individual resident's rights to utilize medical cannabis where indicated. The authors developed an innovative program that affords their residents the ability to participate in a state-approved medical cannabis program while remaining compliant with Federal law. As medical cannabis use becomes more widespread and accepted, clinicians providing medical care in healthcare facilities will encounter residents who may benefit from and request this alternative therapy. Studies examining older adults that are utilizing medical cannabis legally have demonstrated significant decreases in prescription medication use, most notably a reduction in opioid analgesic usage. As such, medical cannabis should be viewed as an additional option in the clinician's toolbox of therapeutic interventions for symptom relief.

© 2018 AMDA – The Society for Post-Acute and Long-Term Care Medicine.

Keywords: Medical cannabis, medical marijuana, alternative medicine, skilled nursing facility, symptom management

### Problem/Significance

An essential principle in the practice of geriatric medicine in the skilled nursing facility (SNF) is the need for ongoing drug regimen review, with a keen focus of attention on simplifying medication regimens, avoiding polypharmacy, and eliminating medications with potentially harmful side effect profiles. As in general outpatient practice, clinicians practicing in the SNF have traditionally considered options for symptom management based on currently available Food and Drug Administration (FDA)-approved over-the-counter and prescription medications. In recent years, however, there has been a significant nationwide resurgence in the use of cannabis as a medical therapy. In fact, to date, 31 states in the US have now approved the use of medical cannabis for a variety of chronic conditions. Given the fact that cannabis remains a Schedule I controlled substance, what role, if any, does medical cannabis play in the SNF?

To begin to answer this question, historical records dating back to China (2700 BC), India (1400 BC), and ancient Greece (77 BC) describe the widespread therapeutic use of the cannabis plant for pain, inflammation, and spasticity.<sup>1</sup> In 1850, cannabis extract was added to the United States Pharmacopeia. During the second half of the 19th century, medical use of cannabis became a commonly prescribed remedy, well documented in the medical literature for the treatment of rheumatic pain, spasm, seizure, emesis, and

neuralgia. In 1915, Sir William Osler, the father of modern medicine, describes cannabis as the "most satisfactory remedy" for migraine.<sup>2</sup>

Despite the role that medical cannabis held as a botanical therapy with a documented history supporting its use for symptom management, therapeutic use of cannabis ceased during the early 20th century. Prohibition-era social and political factors in the United States led to a significant national stigma associated with cannabis use for both medicinal and recreational purposes. The passage of the Marihuana Tax Act of 1937 as well as subsequent legislation resulted in the criminalization of possession and/or use of cannabis for any purpose. The Controlled Substances Act of 1970 categorized cannabis as a Schedule I drug, labeling it as a substance with no currently accepted medical use and with high potential for abuse.

During the 1990s, the discovery of the primary endogenous cannabinoids arachidonylethanolamine and 2-arachidonoylglycerol and their corresponding CB1 and CB2 receptor sites both in the central nervous system and peripherally led to a major resurgence of interest in the therapeutic benefits of cannabis. Since the legalization of medical cannabis in the state of California in 1996, 30 additional states and the District of Columbia have passed similar legislation legalizing medical cannabis use. Nevertheless, cannabis possession and administration continue to remain illegal at the Federal level, given its continued status as a Schedule I controlled substance. As a recipient of Medicare and Medicaid funding, SNFs are required to remain in compliance with Federal law. As such, neither can the SNF purchase and store medical cannabis nor can facility nursing staff administer it to residents, as is common practice for all other medications and treatments.

The authors declare no conflicts of interest.

\* Address correspondence to Zachary J. Palace, MD, CMD, Medicine, Hebrew Home at Riverdale, 5901 Falsdale Ave, Bronx, NY 10471.

E-mail address: zachary.palace@hebrewhome.org (Z.J. Palace).

<https://doi.org/10.1016/j.jamda.2018.11.013>

1525-8610/© 2018 AMDA – The Society for Post-Acute and Long-Term Care Medicine.

BUSINESS INSURANCE.

CANNABIS & HEMP CONFERENCE

OCT 24-25 | MARRIOTT MARQUIS | NEW YORK

#BI\_CANNABIS

# *European Journal of Internal Medicine,* March 2018 Volume 49:44-50.

- Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly.**

-2736 patients above 65 years of age began cannabis treatment and responded to the questionnaire. Mean age was  $74.5 \pm 7.5$  years. The most common indications for cannabis treatment were pain (66.6%) and cancer (60.8%).

- Results:**

-After six months of treatment, 93.7% of the respondents reported improvement in their condition and the reported pain level was reduced from a median of 8 on a scale of 0-10 to a median of 4.

-35% reported decrease in total number of meds or dosage.

-18.1% stopped using opioid analgesics or reduced their dose.

- Adverse effects:**

- Falls (21.9%), Dizziness (9.7%), dry mouth (7.1%)

- Conclusion:**

- Therapeutic use of cannabis may decrease the use of other prescription medicines, including opioids.

**BUSINESS INSURANCE.**

**CANNABIS & HEMP CONFERENCE**

**OCT 24-25 | MARRIOTT MARQUIS | NEW YORK**

**#BI\_CANNABIS**

# *Health Affairs, July 6, 2016*

- Question: Is there data that medical cannabis is effective as a medication?
- Data source: Medicare Part D enrollees from 2010 to 2013, in District of Columbia and 17 states where medical cannabis laws were enacted.
- Data collected: Total number of prescriptions filled during the study period was measured.

BUSINESS INSURANCE

**CANNABIS & HEMP CONFERENCE**

OCT 24-25 | MARRIOTT MARQUIS | NEW YORK

#BI\_CANNABIS

# *Health Affairs, July 6, 2016*

- Findings: Use of prescription drugs for pain, depression, seizures, anxiety, nausea, psychoses, and sleep disorders decreased significantly, once a medical marijuana law was implemented.
- National reductions in Medicare program and enrollee spending when states implemented medical marijuana laws were estimated to be \$165.2 million/year in 2013.
- Conclusions: The availability of medical marijuana has a significant effect on prescribing patterns and spending in Medicare Part D.

BUSINESS INSURANCE.

**CANNABIS & HEMP CONFERENCE**

OCT 24-25 | MARRIOTT MARQUIS | NEW YORK

**#BI\_CANNABIS**

# Conclusions

- Wealth of historical clinical experience.
- Limited high quality scientific clinical trials.
- Symptom management – spasticity, pain, emesis, seizure.
- Clinical decision-making should always be individualized.
- Residing in a NH should not be a contraindication to use.

BUSINESS INSURANCE.

**CANNABIS & HEMP CONFERENCE**

OCT 24-25 | MARRIOTT MARQUIS | NEW YORK

#BI\_CANNABIS